🔗 Share this article

Given that the United States continues making unprecedented revisions to its immunization schedules, one figure has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by questioning COVID-19 shots during the pandemic and has concentrated on possible fatalities after COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Program

Health officials planned to reveal radical revisions to the childhood vaccination calendar recently, synchronizing the US with the Danish national calendar, according to reports – a substantial departure that would place the US out of alignment with much of the international standard with no evidence for benefit. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Dr. Høeg is listed to speak at the gathering. She was recently named acting director of the FDA’s CDER, the fifth person to lead the division this calendar year.

A New Direction at the FDA

Høeg's temporary position could signify a closer partnership between the drug and vaccine divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for ending some pediatric immunization guidelines in the US to become more similar to Denmark's approach, a country with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccines – usually the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Qualifications

Høeg has no obvious track record in medication creation, approval processes or management, which has been typical for previous directors of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She lacks experience in managing a sizeable institution. She lacks background in industry regulation.”

Former heads of the center would “grasp regulatory frameworks and the research of drug development”, said Dr. Janet Woodcock. “Objectively, she lacks the type of experience that prior appointees who ran the center have had.”

This division has an immense range of responsibilities at the agency, Woodcock pointed out.

“The public just pays attention on the novel medication approvals, but the generic drug division clears numerous generic drugs. There is also a biosimilars program, OTC medication office and so forth, and every single one need to be looked after,” she explained. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial administrative component to the job, which manages more than 5,000 employees. “It is a massive leadership role, if you execute it properly,” she added.

Agency Reaction and Controversial Initiatives

In response to inquiries about Dr. Høeg's qualifications and whether this assignment signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson stated that the “inquiries rely on incorrect premises”.

“Her resume matches the duties of her job,” the representative explained, noting the months Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a disputed one-day therapy clearance system that allegedly troubled her former heads. “By what process are these medications being picked for this fast-track system? Who takes the decisions?” Dr. Howard said. “There is a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he said, “the FDA looks to be trending towards more relaxed rules of most medications, aside from vaccines.”

Public Track Record on Vaccines

Regarding vaccines, Høeg has a clearer, if problematic, track record, critics observe. She released a study using non-validated volunteer-provided data to determine the incidence of myocarditis after Covid immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the new government encompassed changing regulations for recently developed shots and ending “unnecessary” immunizations, she said post-election on a online show. At the FDA, Høeg has reportedly suggested excluding young men from getting Covid vaccinations.

“She is an thorough dogmatist who starts off with her preconceived notions and reverse-engineers to accommodate the data in a highly deceptive, untruthful fashion,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg aligned with other contrarians, {like|